Exenatide
- Generic Name
- Exenatide
- Brand Names
- Bydureon, Byetta
- Drug Type
- Biotech
- CAS Number
- 141758-74-9
- Unique Ingredient Identifier
- 9P1872D4OL
- Background
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
- Indication
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.
- Associated Conditions
- Type 2 Diabetes Mellitus
Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00701935
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 820
- Registration Number
- NCT00676338
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
🇮🇱Research SIte, Tel-Hashomer, Israel
Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00672399
- Locations
- 🇬🇧
Reseach Site, Derriford, Plymouth, United Kingdom
🇬🇧Research Site, Leeds, West Yorkshire, United Kingdom
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 41
- Registration Number
- NCT00667732
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Medstar Research Institute, Washington DC, District of Columbia, United States
Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 122
- Registration Number
- NCT00658021
- Locations
- 🇿🇦
Research Site, Verulam, South Africa
Role of Exenatide in NASH-a Pilot Study
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 8
- Registration Number
- NCT00650546
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸Kansas City VA Medical Center, Kansas City, Missouri, United States
🇺🇸Fort Sam Houston, San Antonio, Texas, United States
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 467
- Registration Number
- NCT00641056
- Locations
- 🇨🇳
Research Site, Taoyuan, Taiwan
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: placebo tabletDrug: placebo once weekly
- First Posted Date
- 2008-03-17
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00637273
- Locations
- 🇲🇽
Research Site, Toluca, Mexico
CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: any human insulin or analog insulin(s) given in any regimen by subcutaneous injection
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2515
- Registration Number
- NCT00635492
- Locations
- 🇸🇪
Research Site, Vastervik, Sweden
🇩🇪Research, Birkenfeld, Germany
Bioenergetic Alterations After Exenatide Administration
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 28
- Registration Number
- NCT00623545
- Locations
- 🇺🇸
Univ Wisconsin Hospital and Clinics, Madison., Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.